Tolerability of ragweed allergy immunotherapy in patients with allergic rhinoconjunctivitis.

Trial Profile

Tolerability of ragweed allergy immunotherapy in patients with allergic rhinoconjunctivitis.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2013

At a glance

  • Drugs Short ragweed pollen allergen extract (Ragwitek) (Primary)
  • Indications Allergic rhinoconjunctivitis
  • Focus Adverse reactions
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 27 Feb 2013 New trial record
    • 22 Feb 2013 Results presented at the 69th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top